ClinicalTrials.gg
CompletedNCT05835622EXHOMESEPUpdated Sep 25, 2026

Clinical Investigation of the Quality of Life Benefit of Using a Home Walking Exoskeleton for a Population of Multiple Sclerosis Patients.

An interventional study of Keeogo and adviced home practice in Multiple Sclerosis, sponsored by Pôle Saint Hélier. Completed at 6 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Pôle Saint Hélier · Not applicable, Interventional, and Supportive care

How we know

Updated Sep 25, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 376 studies in Multiple Sclerosis with a site in France — 63 open to participants now, 92 under way, 18 of them phase 3. Multiple Sclerosis · France.

Enrollment
222nd of 244
28 · median 144
Started
2024
with 13 others
No phase
110 of 376
32 open now
Registered
321st of 376
by date

Among the 376 studies in Multiple Sclerosis with a site in France, this one is the 222nd largest by enrollment of the 244 interventional ones that give a count, is one of 14 that started in 2024, is one of 110 with no phase, and was the 321st registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

63 of the 376 studies in Multiple Sclerosis with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 376 studies in Multiple Sclerosis with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical investigation is to evaluate the effectiveness of home use of a lightweight robotic lower limb exoskeleton as a walking aid device on quality of life in patients with multiple sclerosis with gait disorders.

Participants will wear an exoskeleton (Keeogo) for 8 weeks at home during the experimental phase. This phase is compared to an 8-week control phase at home with advice on regular physical activity adapted to their abilities.

Read the detailed description

It is a multicenter, controlled, randomized, cross-over, open-label clinical investigation.

Patients with multiple sclerosis with an Expanded Disability Status Scale (EDSS) between 5 and 6.5,living at home and using an assistive device for walking will be included.

After enrollment, patients will be randomised in one of the 2 study-arm.

  • Arm A: experimental phase / Wash-Out (WO) (8 weeks) / control phase
  • Arm B: control phase / WO (8 weeks) / experimental phase

During the experimental phase, patients will receive a Keeogo specific training for five days. The purpose of this training programme is to ensure familiarity and acceptance of the device. Then, the patients will take Keeogo home and will have to use the device as much as possible indoors and outdoors for seven weeks.

During the control phase, patients will be at home for eight weeks with advice on regular physical activity adapted to their abilities.

After the second phase, all patients will have a 3 months of follow-up.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patient with multiple sclerosis according to the revised Mac Donald diagnostic criteria (2017) in the relapsing-remitting form more than 6 months from a relapsing or progressive period.
  • An Expanded Disability Status Scale (EDSS) between 5 and 6.5 on the EDSS scale (Kurtzke 1983)
  • Living at home
  • Using a walking aid
  • 18 years old or older
  • Have freely consented to participate in this study
  • To be more than 1m52 tall
  • Hip Manual Muscle Testing (MMT) score ≥ 3+ (flexors and expanders)
  • Knee Manual Muscle Testing (MMT) score ≥ 2 (flexors and expanders)
  • Berg scale (BBS) score > 20
  • Patient affiliated with a social security plan or beneficiary of such a plan.

Non-Inclusion Criteria:

  • Impaired comprehension preventing completion of the protocol
  • Inability to walk without assistance for 10 minutes
  • Have a rehabilitation stay scheduled during the follow-up period of the clinical investigation
  • Diagnosed psychiatric conditions that may have an impact on the experience of withdrawal of technical assistance at the end of the protocol
  • Severe cognitive impairment (\<24)
  • Person deprived of liberty by a judicial or administrative decision
  • A person under psychiatric care or admitted to a health or social institution for purposes other than research.
  • Spasticity >3 on the Held and Tardieu scale affecting the hamstring, quadriceps, adductor or sural triceps muscles
  • Complete paralysis of the lower limbs
  • Severe osteoporosis
  • Hip and/or knee replacements that would sufficiently limit range of motion for walking and sitting or squatting
  • Severe vascular disorders of the lower limbs
  • Existing wounds or skin lesions where the device is worn
  • Pregnant woman or postpartum woman who has not completed lumbopelvic recovery
  • Orthopedic disorders of the lower limb that may prevent satisfactory adjustment of Keeogo
  • Uncontrolled epilepsy or tremors
  • Uncontrolled autonomic dysreflexia
  • Severe balance disorders, neurological disorders (any condition that prevents the safe control of balance and/or movement of the limbs at all times while wearing the Keeogo System)
  • Conditions that prevent safe moderate-intensity exercise
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Other
    Arm A

    8 weeks of using keeogo at home (experimental phase) followed by 8 weeks of wash-up and then followed by 8 weeks of recommended home practise (control phase).

    Device: Keeogo · Other: adviced home practice

  • Other
    Arm B

    8 weeks of recommended home practise (control phase) followed by 8 weeks of wash-up and then followed by 8 weeks of using keeogo at home (experimental phase)

    Device: Keeogo · Other: adviced home practice

Interventions

  • DeviceKeeogo

    Keeogo is exoskeleton for walking assistance

  • Otheradviced home practice

    health tips for regular and appropriate physical activity

06

What researchers measure

Primary outcomes

  1. Evolution of the quality of life assessed with the "Functional Assessment Of Multiple Sclerosis" questionnaire (change between two time points)

    The Functional Assessment Of Multiple Sclerosis (FAMS) is a self-administered health questionnaire related to quality of life for patients with multiple sclerosis

    Time frame: Screening visit and visit after experimental phase (Week 8 for Arm A; Week 24 for Arm B)

Secondary outcomes

  1. Walking and balancing performance with the Keeogo exoskeleton (1)

    Measured by 2 minutes walking test

    Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)

  2. Walking and balancing performance with the Keeogo exoskeleton (2)

    Measured by 10 meter walking test

    Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)

  3. Walking and balancing performance with the Keeogo exoskeleton (3)

    Measured by the Timed up and go Test

    Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)

  4. Walking and balancing performance with the Keeogo exoskeleton (4)

    Measured by Functional Stair Test (FST)

    Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)

  5. Walking and balancing performance with the Keeogo exoskeleton (5)

    Measured by the Sit to Stand Test (SST)

    Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)

  6. Walking and balancing performance with the Keeogo exoskeleton (6)

    Evaluations of spatio-temporal gait parameters using an instrumented walking system (Gaitrite®, Vicon® or Locometer® for example)

    Time frame: after experimental phase (Week 8 for Arm A; Week 24 for Arm B)

  7. Spasticity of the quadriceps, hamstrings and abductors muscles

    Assessed manually by the Held and Tardieu Test

    Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)

  8. Sense of self-efficacy

    Measured by the Rosenberg Self-Efficacy Questionnaire

    Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)

  9. The average daily distance travelled

    Measured by inertial units tracing the daily activity of the participants (descriptive daily distance travelled)

    Time frame: At study visits (Week 8, Week 24, Month 9)

  10. Fatigue

    Measured by the French version of the fatigue impact scale in multiple sclerosis (EMIF-SEP) scored from 0 to 100% a low score is a better outcome

    Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)

  11. Anxiety and depression

    Measured by the Hospital Anxiety and Depression score (HAD) scored from 0 to 21 for both subtitles (Anxiety and depression) a low score is a better outcome

    Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)

  12. Satisfaction with this new home technical aid

    Evaluated via the French version of the QUEST questionnaire (ESAT questionnaire)

    Time frame: After experimental phase (Week 8 for Arm A; Week 24 for Arm B)

  13. Projection in use

    Evaluated by a usage questionnaire (UTAUT-based already used in a walking exoskeleton context)

    Time frame: After experimental phase (Week 8 for Arm A; Week 24 for Arm B)

  14. Walking and balancing performance without exoskeleton (1)

    Measured by the 2 minutes walking test

    Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)

  15. Walking and balancing performance without exoskeleton (2)

    Measured by the 10 meter walking test

    Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)

  16. Walking and balancing performance without exoskeleton (3)

    Measured by the Timed up and go Test

    Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)

  17. Walking and balancing performance without exoskeleton (4)

    Measured by the Functional Stair Test (FST)

    Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)

  18. Walking and balancing performance without exoskeleton (5)

    Measured by the Sit to Stand Test (SST)

    Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)

  19. Walking and balancing performance without exoskeleton (6)

    Evaluations of spatio-temporal gait parameters using an instrumented walking system (Gaitrite®, Vicon® or Locometer® for example)

    Time frame: At all study visits (Screening, Week 8, Week 16, Week 24, Month 9)

07

Study locations

6 sites
  • Hospices Civils de Lyon - Hôpital Henry Gabrielle
    Saint-Genis-Laval, Auvergne-Rhône-Alpes 69230, France
  • Pôle Saint Hélier
    Rennes, Brittany Region 35000, France
  • Hôpital Saint Philibert-Groupement des Hôpitaux de l'Institut Catholique de Lille
    Lomme, Hauts-de-France 59160, France
  • Centre de rééducation Fonctionnelle Propara-Montpellier
    Montpellier, Occitanie 34090, France
  • CHU Angers- SSR Les Capucins
    Angers, Pays de la Loire Region 49103, France
  • CHU Nantes site de Saint Jacques
    Nantes, Pays de la Loire Region 44093, France
08

References and documents

Publications

  • Leblong E, Billot M, Cecile D, Gelis A, Mickael D, Jacquin-Courtois S, Gross R, Le Meur C, Linda B, Carole A, Benoit N, Bastien F, Philippe G. Home-based exoskeleton use to improve quality of life in patients with multiple sclerosis: study protocol of a multicentre, randomised, cross-over trial. BMJ Open. 2026 Jun 22;16(6):e115237. doi: 10.1136/bmjopen-2025-115237. PubMed 42331578 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Sep 2026, 31 months.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's 31 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Oct 2026 → Sep 2026 and completion Oct 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2023
First posted
Apr 28, 2023
StartActual
Feb 1, 2024
Primary completionActual
Sep 18, 2026was Oct 2026
CompletionActual
Sep 18, 2026was Oct 2026
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Sep 25, 2026
Primary completion
Oct 2026→Sep 18, 2026 (actual)
Sep 25, 2026
Study completion
Oct 2, 2026→Sep 18, 2026 (actual)
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Active, not recruiting→Completed
    Primary completion Oct 2026→Sep 18, 2026 (now actual)
    Study completion Oct 2, 2026→Sep 18, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05835622
Lead sponsor
Pôle Saint Hélier
Responsible party
Sponsor
First posted
Apr 28, 2023
Start date
Feb 1, 2024
Primary completion
Sep 18, 2026
Completion
Sep 18, 2026
Last update
Sep 25, 2026

Study contacts

Philippe Gallien, Doctor
principal investigator · Pole Saint-Hélier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion